Abstract
Glioblastoma is the most common adult malignant primary brain tumor, and carries a dismal prognosis. After initial standard radiation therapy and chemotherapy with temozolomide, few standard chemotherapy options are available. In the last two decades, a growing understanding of molecular pathogenesis of glioblastoma has turned our focus toward targeted therapy. This review will discuss our current understanding of gliomagenesis and highlight the clinical attempts to manipulate these vital pathways, describing past and current studies, and future directions.
Keywords: Cell signaling, glioblastoma, gliomagenesis, monoclonal antibodies, targeted therapy, tyrosine kinase inhibitors.
Current Cancer Therapy Reviews
Title:Targeted Therapy for Glioblastoma: Lessons Learned and Future Directions
Volume: 11 Issue: 1
Author(s): Nicole A Shonka, Suprit Gupta and Pankaj K. Singh
Affiliation:
Keywords: Cell signaling, glioblastoma, gliomagenesis, monoclonal antibodies, targeted therapy, tyrosine kinase inhibitors.
Abstract: Glioblastoma is the most common adult malignant primary brain tumor, and carries a dismal prognosis. After initial standard radiation therapy and chemotherapy with temozolomide, few standard chemotherapy options are available. In the last two decades, a growing understanding of molecular pathogenesis of glioblastoma has turned our focus toward targeted therapy. This review will discuss our current understanding of gliomagenesis and highlight the clinical attempts to manipulate these vital pathways, describing past and current studies, and future directions.
Export Options
About this article
Cite this article as:
Shonka A Nicole, Gupta Suprit and Singh K. Pankaj, Targeted Therapy for Glioblastoma: Lessons Learned and Future Directions, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/157339471101150706122425
DOI https://dx.doi.org/10.2174/157339471101150706122425 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Melanocortins and their Receptors and Antagonists
Current Drug Targets Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem
Current Nanoscience MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment
Current Drug Targets - Inflammation & Allergy DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Role of Mu and Delta Opioid Receptors in Alcohol Drinking Behaviour
Current Drug Abuse Reviews Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design